Masoprocol
As of the edition of 20 October 2026, Masoprocol is a small molecule: marketed, first approved in 1992 (US); acts on ERBB2 and IGF1R; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1992
- Kind
- Small molecule
- Brand name
- Actinex
- First approved
- 4 September 1992 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Univ Arizona Cancer Center
- Registered trials
- 2, 2 stopped early
- Disease areas
- Cancer; Urinary and reproductive
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Masoprocol.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Earlier holder | 1992 to now |
| Univ Arizona Cancer Center | Acquired holder | 2003 to now |